Operating
Change in Deferred Revenue
Year-over-year, this metric grew by 94.0%, from -$27.32M to -$1.63M. Over 3 years (FY 2022 to FY 2025), Change in Deferred Revenue shows an upward trend with a -7.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026
How to read this metric
An increase indicates strong future demand and cash inflow, while a decrease suggests revenue recognition from previously collected cash.
Detailed definition
This represents the net change in cash received from customers for goods or services that have not yet been delivered or...
Peer comparison
Common in long-term contract businesses like LNG; peers with similar business models often show significant deferred revenue balances.
Metric ID:
change_in_deferred_revenueHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$23.94M | -$8.35M | -$12.33M | $158.00K | -$12.47M | -$41.28M | -$8.85M | $21.72M | $24.47M | $17.69M | -$28.56M | -$190.94M | -$3.13M | -$12.81M | -$27.32M | -$13.08M | -$12.54M | $0.00 | -$1.63M |
| QoQ Change | — | +65.1% | -47.6% | +101.3% | <-999% | -231.2% | +78.6% | +345.4% | +12.7% | -27.7% | -261.5% | -568.5% | +98.4% | -309.3% | -113.3% | +52.1% | +4.1% | +100.0% | — |
| YoY Change | — | — | — | +100.7% | -49.2% | — | +28.2% | >999% | +296.3% | +142.9% | -222.7% | -979.3% | -112.8% | -172.4% | +4.3% | +93.2% | -300.6% | +100.0% | +94.0% |
Range-$190.94M – $24.47M
CAGR-44.9%
Avg YoY Growth+844.4%
Median YoY Growth+28.2%
Current Streak4 quarters growth
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's change in deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported change in deferred revenue of -$1.63M in Q1 2026.
- How has Alnylam Pharmaceuticals's change in deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's change in deferred revenue increased by 94.0% year-over-year, from -$27.32M to -$1.63M.
- What is the long-term trend for Alnylam Pharmaceuticals's change in deferred revenue?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's change in deferred revenue has grown at a -7.0% compound annual growth rate (CAGR), from -$65.91M to -$52.94M.
- What does change in deferred revenue mean?
- The net change in payments received from customers for services not yet provided.